Advertisement
Screener

GSK plc (GLAXF) Form 6-K: Report of foreign private issuer, 2019

2.1 / 5 stars · 17/40 Roast Me

Add as a preferred source on Google

GSK plc Form 6-K: Report of foreign private issuer

Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.

  • 2019-12-23: Form 6-K; Period of report 2019-12-23; Description VIIV HEALTHCARE RECEIVES COMPLETE RESPONSE LETTER; Document a7900x.htm.
  • 2019-12-18: Form 6-K; Period of report 2019-12-18; Description DIRECTOR/PDMR SHAREHOLDING; Document a3936x.htm.
  • 2019-12-18: Form 6-K; Period of report 2019-12-18; Description DIRECTOR/PDMR SHAREHOLDING; Document a3905x.htm.
  • 2019-12-17: Form 6-K; Period of report 2019-12-17; Description BLOCKLISTING APPLICATION; Document a1328x.htm.
FiledFormPeriod of reportDescriptionDocument
2019-12-236-K2019-12-23VIIV HEALTHCARE RECEIVES COMPLETE RESPONSE LETTERa7900x.htm
2019-12-186-K2019-12-18DIRECTOR/PDMR SHAREHOLDINGa3936x.htm
2019-12-186-K2019-12-18DIRECTOR/PDMR SHAREHOLDINGa3905x.htm
2019-12-176-K2019-12-17BLOCKLISTING APPLICATIONa1328x.htm
2019-12-136-K2019-12-13DIRECTOR/PDMR SHAREHOLDINGa8933w.htm
2019-12-116-K2019-12-11DIRECTOR/PDMR SHAREHOLDINGa5785w.htm
2019-12-056-K2019-12-05VIIV SUBMITS NDA TO FDA FOR FOSTEMSAVIRa8341v.htm
2019-12-046-K2019-12-04EMMA WALMSLEY - EXTERNAL APPOINTMENTa7250v.htm
2019-12-026-K2019-12-02TOTAL VOTING RIGHTSa3996v.htm
2019-12-026-K2019-12-02DIRECTOR/PDMR SHAREHOLDINGa4085v.htm
2019-11-266-K2019-11-26BLOCK LISTING INTERIM REVIEWa7388u.htm
2019-11-126-K2019-11-12DIRECTOR/PDMR SHAREHOLDINGa1691t.htm
2019-11-086-K2019-11-08DIRECTOR/PDMR SHAREHOLDINGa8649s.htm
2019-11-066-K2019-11-06DIRECTOR/PDMR SHAREHOLDINGa5430s.htm
2019-11-046-K2019-11-04DIRECTOR/PDMR SHAREHOLDINGa2247s.htm
2019-11-016-K2019-11-01DIRECTOR/PDMR SHAREHOLDINGa0532s.htm
2019-11-016-K2019-11-01TOTAL VOTING RIGHTSa9658r.htm
2019-10-316-K2019-10-31DIRECTOR/PDMR SHAREHOLDINGa8484r.htm
2019-10-306-K2019-10-30DIRECTOR/PDMR SHAREHOLDINGa7015r.htm
2019-10-306-K2019-10-303RD QUARTER RESULTSa6482r.htm
2019-10-216-K2019-10-21GSK DIVESTS TWO TRAVEL VACCINES TO BAVARIAN NORDICa4659q.htm
2019-10-156-K2019-10-15DIRECTOR/PDMR SHAREHOLDINGa9658p.htm
2019-10-156-K2019-10-15DIRECTOR/PDMR SHAREHOLDINGa9618p.htm
2019-10-156-K2019-10-15DIRECTOR/PDMR SHAREHOLDINGa9653p.htm
2019-10-156-K2019-10-15DIRECTOR/PDMR SHAREHOLDINGa9652p.htm
2019-10-116-K2019-10-11DIRECTOR/PDMR SHAREHOLDINGa6937p.htm
2019-10-116-K2019-10-11DIRECTOR/PDMR SHAREHOLDINGa6821p.htm
2019-10-106-K2019-10-10DIRECTOR/PDMR SHAREHOLDINGa5366p.htm
2019-10-016-K2019-10-01DIRECTOR/PDMR SHAREHOLDINGa4224o.htm
2019-10-016-K2019-10-01TOTAL VOTING RIGHTSa3696o.htm
2019-09-306-K2019-09-30DATA SHOW ANTI-TUMOUR ACTIVITY WITH ICOS AGONISTa0547o.htm
2019-09-306-K2019-09-30PRIMA SHOWS ZEJULA IMPROVES PFS IN OVARIAN CANCERa0546o.htm
2019-09-266-K2019-09-26DIRECTOR/PDMR SHAREHOLDINGa8735n.htm
2019-09-176-K2019-09-17DIRECTOR/PDMR SHAREHOLDINGa6794m.htm
2019-09-116-K2019-09-11DIRECTOR/PDMR SHAREHOLDINGa6273m.htm
2019-09-046-K2019-09-04DIRECTOR/PDMR SHAREHOLDINGa2656l.htm
2019-09-046-K2019-09-04DIRECTOR/PDMR SHAREHOLDINGa2256l.htm
2019-09-046-K2019-09-04DIRECTOR/PDMR SHAREHOLDINGa1884l.htm
2019-09-036-K2019-09-03TOTAL VOTING RIGHTSa9049k.htm
2019-08-236-K2019-08-23GSK - POSITIVE RESULTS FROM PIVOTAL DREAMM-2 STUDYa0431k.htm
2019-08-226-K2019-08-22VIIV RESULTS POSITIVE FOR EVERY 2 MONTH INJECTIONa8510j.htm
2019-08-216-K2019-08-21GSK SUBMITS REGULATORY FILE IN JAPAN: DAPRODUSTATa7500j.htm
2019-08-126-K2019-08-12DIRECTOR/PDMR SHAREHOLDINGa7685i.htm
2019-08-016-K2019-08-01EU APPROVAL FOR NUCALA SELF-ADMINISTRATIONa6210h.htm
2019-08-016-K2019-08-01TOTAL VOTING RIGHTSa6085h.htm
2019-08-016-K2019-08-01GSK COMPLETES TRANSACTION WITH PFIZER FOR NEW JVa4700h.htm
2019-07-306-K2019-07-30DIRECTOR/PDMR SHAREHOLDINGa2503h.htm
2019-07-296-K2019-07-29VIIV SUBMITS CABOTEGRAVIR TO EMA FOR HIV INJECTIONa9505g.htm
2019-07-246-K2019-07-242ND QUARTER RESULTSa5920g.htm
2019-07-246-K2019-07-24DIRECTOR/PDMR SHAREHOLDINGa6364g.htm
2019-07-246-K2019-07-24VIIV 2DR TANGO SWITCH STUDY POSITIVE AT 48 WEEKSa6182g.htm
2019-07-246-K2019-07-24VIIV GEMINI STUDIES SHOW HIGH EFFICACY AT 96 WEEKSa6167g.htm
2019-07-246-K2019-07-24NON-EXECUTIVE CHAIRMANa5625g.htm
2019-07-226-K2019-07-22VIIV PRESENTS 96-WEEK DATA FROM PHASE III STUDYa3315g.htm
2019-07-156-K2019-07-15DIRECTOR/PDMR SHAREHOLDINGa6042f.htm
2019-07-156-K2019-07-15DIRECTOR/PDMR SHAREHOLDINGa6041f.htm
2019-07-156-K2019-07-15DIRECTOR/PDMR SHAREHOLDINGa6037f.htm
2019-07-156-K2019-07-15DIRECTOR/PDMR SHAREHOLDINGa5495fdocx.htm
2019-07-156-K2019-07-15POSITIVE RESULTS IN PHASE 3 PRIMA STUDY OF ZEJULAa4582f.htm
2019-07-126-K2019-07-12DIRECTOR/PDMR SHAREHOLDINGa4377f.htm
2019-07-126-K2019-07-12DIRECTOR/PDMR SHAREHOLDINGa4346f.htm
2019-07-106-K2019-07-10DIRECTOR/PDMR SHAREHOLDINGa1393f.htm
2019-07-106-K2019-07-10VIIV SWITCH STUDY SHOWS 2DR AS EFFECTIVE AS 3DRa0095f.htm
2019-07-036-K2019-07-03VIIV RECEIVES DOVATO EU MARKETING AUTHORISATIONa2769e.htm
2019-07-016-K2019-07-01TOTAL VOTING RIGHTSa0485e.htm
2019-06-126-K2019-06-12DIRECTOR/PDMR SHAREHOLDINGa0226c.htm
2019-06-076-K2019-06-07FDA APPROVAL FOR NUCALA SELF-ADMINISTRATIONa4564b.htm
2019-06-046-K2019-06-04CHMP POSITIVE ON GSK S NUCALA SELF ADMINISTRATIONa0489b.htm
2019-06-036-K2019-06-03TOTAL VOTING RIGHTSa9754a.htm
2019-05-246-K2019-05-24DIRECTOR/PDMR SHAREHOLDINGa1447a.htm
2019-05-206-K2019-05-20DIRECTOR/PDMR SHAREHOLDINGa5881z.htm
2019-05-136-K2019-05-13BLOCK LISTING INTERIM REVIEWa8832y2.htm
2019-05-136-K2019-05-13DIRECTOR/PDMR SHAREHOLDINGa8701y.htm
2019-05-086-K2019-05-08RESULT OF AGM & GMa4379y.htm
2019-05-026-K2019-05-02TRELEGY ELLIPTA ASTHMA STUDY MET PRIMARY ENDPOINTa9498x.htm
2019-05-016-K2019-05-01DIRECTOR/PDMR SHAREHOLDINGa7913x.htm
2019-05-016-K2019-05-011ST QUARTER RESULTSa7578x.htm
2019-05-016-K2019-05-01TOTAL VOTING RIGHTSa7836x.htm
2019-04-296-K2019-04-29VIIV SUBMITS NDA FOR HIV MONTHLY 2 DRUG INJECTABLEa4055x.htm
2019-04-266-K2019-04-26VIIV RECEIVES CHMP POSITIVE OPINION FOR DOVATOa3001x.htm
2019-04-166-K2019-04-16DIRECTOR/PDMR SHAREHOLDINGa4073w2.htm
2019-04-166-K2019-04-16DIRECTOR/PDMR SHAREHOLDINGa4075w.htm
2019-04-166-K2019-04-16DIRECTOR/PDMR SHAREHOLDINGa4059w.htm
2019-04-166-K2019-04-16DIRECTOR/PDMR SHAREHOLDINGa4041w.htm
2019-04-156-K2019-04-15DIRECTOR/PDMR SHAREHOLDINGa2400w.htm
2019-04-126-K2019-04-12DIRECTOR/PDMR SHAREHOLDINGa1080w.htm
2019-04-126-K2019-04-12DIRECTOR/PDMR SHAREHOLDINGa1098w.htm
2019-04-116-K2019-04-11DIRECTOR/PDMR SHAREHOLDINGa9647v.htm
2019-04-096-K2019-04-09FDA APPROVES VIIVS TWO-DRUG HIV REGIMEN, DOVATOa5074v.htm
2019-04-026-K2019-04-02PUBLICATION OF AGM AND GM SHAREHOLDER DOCUMENTSa8668u.htm
2019-04-026-K2019-04-026-Kd730568d6k.htm
2019-04-016-K2019-04-01TOTAL VOTING RIGHTSa7386u.htm
2019-03-286-K2019-03-28GSK REPORTING CHANGES - PRODUCT SALES AND IFRS 16a3830u20.htm
2019-03-256-K2019-03-25DIRECTOR/PDMR SHAREHOLDINGa9404t.htm
2019-03-256-K2019-03-256-Kd724186d6k.htm
2019-03-216-K2019-03-21GSK ANNOUNCES FURTHER POSITIVE DATA FROM DREAMM-1a6382t.htm
2019-03-196-K2019-03-19DATA FROM GARNET STUDY EVALUATING DOSTARLIMABa3633t.htm
2019-03-186-K2019-03-18GSK ANNUAL REPORT 2018 ON FORM 20-Fa0969t.htm
2019-03-126-K2019-03-12DIRECTOR/PDMR SHAREHOLDINGa6459s.htm
2019-03-126-K2019-03-12ANNUAL FINANCIAL REPORTa6307s.htm
Advertisement